FiercePharmaOriginal article
{"a":[{"_":"Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer","$":{"href":"/pharma/jazz-withdraw-zepzelca-fda-second-line-small-cell-lung-cancer","hreflang":"en"}}]}
RegulatoryZepzelcaNegative
AI Analysis
Summary
Jazz Pharmaceuticals has decided to withdraw Zepzelca, a second-line treatment for small cell lung cancer, after a prolonged market struggle. The voluntary withdrawal represents a setback for the company's oncology portfolio.
Outcome Details
Jazz Pharmaceuticals voluntarily withdrawing Zepzelca from the market as a second-line treatment for small cell lung cancer
Importance:6/10
Sentiment:
-0.80
drug withdrawalregulatoryoncologysmall cell lung cancer
Related Companies
Read the original article
Published by FiercePharma on August 4, 2026 9:01 AM